Optimizerx Corp - OPRX STOCK NEWS

OptimizeRx Corp. (Nasdaq: OPRX) has expanded its strategic relationship with a major pharma client, resulting in a multi-solution, multi-brand program with a total in-year commitment of over $10 million. This includes the previously mentioned $6 million DAAP contract, which is still undergoing internal review. The expansion demonstrates the value of OptimizeRx's solutions in driving stronger commercial performance through HCP and DTC marketing alignment.

Key highlights:

• Top 20 pharma clients now average $2.7 million in revenue per client
• Top 3 clients contribute $9.7 million in revenue
• Organic growth remains a key driver for the business
• The company is leveraging its omni-channel platform powered by AI-targeted reach

OptimizeRx Corp. (Nasdaq: OPRX) has launched Micro-Neighborhood® Targeting (MNT) on its Dynamic Audience Activation Platform (DAAP), enhancing Direct-to-Consumer (DTC) marketing for healthcare audiences. This AI-driven technology enables pharmaceutical brands to deliver synchronized DTC and healthcare professional (HCP) campaigns, predicting brand eligibility within the U.S. population.

Key features of DAAP include:

• AI-predicted brand eligibility signals for precise timing of point-of-care messaging
• Integration of real-world data through advanced machine learning models
• Personalized brand communications across various media channels
• Privacy-compliant connection of consumer and clinical data

The platform has demonstrated an average script lift of 25% in HCP audiences over the past three years, offering a more streamlined approach to reach specific patient and provider segments.

OptimizeRx Corp (Nasdaq: OPRX) reported its Q2 2024 financial results, highlighting significant growth despite some challenges. Revenue increased by 36% year-over-year to $18.8 million, while gross profit surged 50% to $11.7 million with a gross margin of 62%. The company secured eight new DAAP deals in Q2. However, GAAP net loss remained at $(4.0) million, slightly improved from $(4.1) million in Q2 2023. Non-GAAP net income was $0.3 million, or $0.02 per diluted share, compared to a non-GAAP net loss of $(0.2) million, or $(0.01) per diluted share, in the year-ago period. Adjusted EBITDA turned positive at $0.5 million from $(0.8) million. Cash holdings increased to $15.0 million as of June 30, 2024. The company reiterated its 2024 guidance for revenue of at least $100 million and Adjusted EBITDA of $11 million. Notable was a timing issue with a $6 million DAAP deal that impacted expected revenues.

OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions, has announced its upcoming second quarter 2024 conference call. The call is scheduled for August 8, 2024, at 4:30 p.m. Eastern Time. Financial results for the quarter ended June 30, 2024, will be released prior to the call. The company's management will host the call, followed by a Q&A session.

Investors and interested parties can join the call using the provided toll-free and international numbers, or access the webcast via the given link. A replay of the call will be available for 12 months through the Investors section of OptimizeRx's website.

OptimizeRx Corp. (Nasdaq: OPRX) has announced its continued commitment to helping pharmaceutical brands navigate the changing landscape of state-level consumer privacy legislation while executing nationwide marketing programs. The company's Micro Neighborhood® Targeting technology enables brands to maintain campaign scale and effectiveness while complying with evolving regulations.

Key points:

• Nearly 50% of the US population is currently covered by state-level consumer data protection regulations, expected to grow to 62% in the next 18 months.
• OptimizeRx's solutions help pharmaceutical marketers maintain campaign scale, reach hard-to-target patient populations, and ensure privacy-safe data handling.
• The company's Dynamic Audience Activation Platform (DAAP) offers privacy-by-design techniques and tailored predictive marketing strategies.

OptimizeRx has announced impressive results from an internal marketing study comparing their AI-guided Dynamic Audience Activation Platform (DAAP) to traditional trigger-based marketing for a Major Depressive Disorder (MDD) therapy. The study revealed that DAAP:

- Identified nearly 3 times more brand-eligible patients per HCP per month
- Delivered 33% higher script lift per HCP per month
- Produced a 75% increase in ROI

These results were achieved in just 3 months, compared to the 6-month trigger-based campaign. The study demonstrates DAAP's superior effectiveness in reaching complex-to-diagnose-and-treat audiences, challenging the status quo of pharma marketing.

OptimizeRx Corp. (Nasdaq: OPRX) has released a white paper highlighting significant gaps in healthcare information shared between doctors and patients. The survey, involving over 170 physicians across seven specialties, reveals that only 16% of patients are well-informed about their conditions and treatments. Misinformation often complicates care discussions, with 59% of physicians rating patient-consumed information as fair-to-poor quality. Despite these challenges, 70% of physicians believe that aligned patient and HCP information can streamline care conversations and improve outcomes. OptimizeRx has initiated its first combined HCP and DTC Dynamic Audience Activation Platform marketing program with a top 5 pharmaceutical client, aiming to bridge these gaps and enhance patient education.

OptimizeRx reported a substantial year-over-year growth for Q1 2024, with revenue increasing by 51% to $19.7 million and gross profit rising by 64% to $12.2 million, representing a 62% gross margin. Despite these gains, the company faced a GAAP net loss of $6.9 million or $0.38 per share, slightly higher than the $6.4 million loss in Q1 2023. Non-GAAP net loss also increased to $2.0 million or $0.11 per share. Adjusted EBITDA improved to a loss of $0.3 million from $2.2 million in Q1 2023. The company secured 9 additional DAAP deals and reported having $15.2 million in cash and equivalents. The firm reaffirmed its 2024 guidance, expecting at least $100 million in revenue and $11 million in adjusted EBITDA. Key performance indicators showed positive trends, with net revenue retention at 116% and revenue per full-time employee at $641,000.

OptimizeRx Corp. (OPRX) is set to participate in several investor conferences including the RBC Capital Markets Global Healthcare Conference, B.Riley Securities Institutional Investor Conference, Stifel Cross Sector Insight Conference, William Blair Annual Growth Stock Conference, and Citizens JMP Medical Devices and Healthcare Services Forum. This move aims to enhance engagement with healthcare professionals and patients, showcasing the company's commitment to innovative healthcare technology solutions.